A research group at the Tyndall National Institute in Cork, Ireland, got an article published in Biomedical Optics Express titled "High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles". The research study uses Lumito's technology with up-converting nanoparticles (UCNPs).
The article examines the use of UCNPs to distinguish different levels of HER2 in CPA (control pellet arrays) and HER2-positive breast cancer tissue. The results demonstrate a good semi-quantitative tool for assessing HER2 in breast cancer tissues.
– It is very positive that our technology is being tested in different types of applications, and we are pleased that the results in the article are promising compared to traditional reference methods, comments CEO Mattias Lundin.
The article is published here: https://opg.optica.org/boe/fulltext.cfm?uri=boe-15-2-900&id=545726
